Amarantus Bioscience Holdings Inc. announced that it has opened an office in Geneva, Switzerland, in preparation for the establishment of a Swiss affiliate. The main purpose of this office is to facilitate interaction with the European biotechnology, pharmaceutical Research and Development and investment communities.

Concurrently, the Company has appointed Mr. Mark Wakefield as Head of Clinical Development across Amarantus' diagnostic and therapeutic divisions. Mr. Wakefield brings over 15 years of experience, of which the last 8 years focused on establishing and implementing development strategies and operations as Head of Clinical Development Operations at Addex Pharma SA (Switzerland).